MURRAY, Utah, Sept. 08, 2022 (GLOBE NEWSWIRE) — R1 RCM Inc. (“R1”) (NASDAQ: RCM) right now introduced the graduation of an underwritten public providing of 15,000,000 shares of its frequent inventory by TCP-ASC ACHI Series LLLP (“TCP-ASC”), a Delaware sequence restricted legal responsibility restricted partnership collectively owned by Ascension Health Alliance and funding funds affiliated with TowerBrook Capital Partners L.P. R1 is not going to obtain any of the proceeds from the sale of the shares being supplied by the promoting stockholder however will bear the prices related to the sale of such shares, apart from any underwriting reductions and commissions.
J.P. Morgan, BofA Securities and Barclays are performing as underwriters for the proposed providing.
A registration assertion on Form S-3 relating to those securities has been filed with the Securities and Exchange Commission (“SEC”) and has turn out to be efficient. The proposed providing can be made solely by means of a prospectus and a free writing prospectus. A replica of the prospectus and the free writing prospectus regarding this providing could also be obtained, when out there, by visiting the SEC’s web site at www.sec.gov. Alternatively, the prospectus and the free writing prospectus could also be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, phone: 866-803-9204 or by emailing [email protected]; BofA Securities, NC1-004-03-43, 200 North College Street, third Floor, Charlotte, NC 28255, Attention: Prospectus Department or by emailing [email protected]; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, phone: 888-603-5847 or by emailing [email protected].
This press launch shall not represent a proposal to promote or a solicitation of a proposal to purchase these securities, nor shall there be any provide or sale of these securities in any state or jurisdiction through which such provide, solicitation or sale could be illegal previous to the registration or qualification beneath the securities legal guidelines of any such state or jurisdiction.
Note Regarding Forward-Looking Statements
Certain of the statements made on this press launch are ahead trying throughout the which means of the Private Securities Litigation Reform Act of 1995, together with statements relating to the scale and phrases of the proposed secondary providing. Actual outcomes or developments could differ materially from these projected or implied in these forward-looking statements. Factors that will trigger such a distinction embrace, with out limitation, dangers and uncertainties associated to the satisfaction of customary closing circumstances associated to the providing and the affect of basic financial, trade or political circumstances within the United States or internationally. There will be no assurance that R1 will be capable to full the providing on the anticipated phrases, or in any respect. You shouldn’t place undue reliance on these forward-looking statements as predictions of future occasions, which statements apply solely as of the date of this press launch. Additional dangers and uncertainties regarding the providing, R1 and its business will be discovered beneath the heading “Risk Factors” in R1 RCM Holdco Inc.’s most up-to-date Annual Report on Form 10-Okay and Quarterly Report on Form 10-Q for the interval ended March 31, 2022, in addition to R1’s Quarterly Report on Form 10-Q for the interval ended June 30, 2022, every filed with the Securities and Exchange Commission. Forward-looking statements symbolize R1’s beliefs and assumptions solely as of the date of this press launch. R1 expressly disclaims any obligation or endeavor to launch publicly any updates or revisions to any forward-looking statements contained herein to mirror any change in its expectations with regard thereto or any change in occasions, circumstances or circumstances on which any such statements are based mostly, besides as could also be required beneath relevant regulation.
About R1 RCM
R1 is a number one supplier of technology-driven options that remodel the affected person expertise and monetary efficiency of hospitals, well being methods, and medical teams. R1’s confirmed and scalable working fashions seamlessly complement a healthcare group’s infrastructure, rapidly driving sustainable enhancements to web affected person income and money flows whereas lowering working prices and enhancing the affected person expertise.
Contacts:
R1 RCM
Investor Relations
Atif Rahim
312.324.5476
[email protected]
Media Relations
Natalie Pacini
415.335.7641 Ext. 43
[email protected]
